The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,569 | -828 |
| Gain on change in accounting estimates on contingent royalty liability | 1,933 | - |
| Change in fair value of financial instruments | -1,845 | 1,355 |
| Inventory write-down for excess & obsolescence | 0 | 178 |
| Loss on contingent liability | 0 | 25 |
| Loss on issuance of financial instruments | - | 0 |
| Stock-based compensation | 23 | 101 |
| Depreciation | 4 | 10 |
| Amortization of intangible asset | 80 | 330 |
| Noncash interest expense | 595 | 1,165 |
| Gain on debt extinguishment | - | 0 |
| Noncash right-of-use amortization | 34 | 61 |
| Net loss on disposal or impairment of property and equipment | 0 | -20 |
| Gain on accounts payable and accrued expenses settlements | 11 | 5,607 |
| Trade accounts receivable | -499 | -4,898 |
| Inventories | -222 | 507 |
| Prepaid and other assets | -423 | -77 |
| Accounts payable | -656 | -709 |
| Accrued expenses and other liabilities | 502 | 514 |
| Accrued compensation | 360 | -245 |
| Contingent liabilities | -50 | -425 |
| Operating lease liabilities | -32 | -62 |
| Net cash, cash equivalents and restricted cash used in operating activities | 336 | -2,359 |
| Payments related to asset acquisition | 0 | 57 |
| Purchases of property and equipment | 0 | 2 |
| Net cash, cash equivalents and restricted cash used in investing activities | 0 | -59 |
| Proceeds from issuance of aditxt notes related party | 0 | 2,425 |
| Borrowings under short-term debt and notes carried at fair value | 0 | 383 |
| Proceeds from reinstatement of merger agreement related party | - | 0 |
| Payments under short term debt and notes carried at fair value | 244 | 383 |
| Net cash, cash equivalents and restricted cash provided by financing activities | -244 | 2,425 |
| Net change in cash, cash equivalents and restricted cash | 92 | 7 |
| Cash and cash equivalents at beginning of period | 741 | - |
| Cash and cash equivalents at end of period | 840 | - |
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)